Prevention of diseases after menopause

Rogerio A Lobo, Susan Ruth Davis, Tobie De Villiers, Anne Gompel, Victor W Henderson, Howard N Hodis, Mary Ann Lumsden, Wendy J Mack, Samuel Shapiro, Rodney Baber

Research output: Contribution to journalArticleResearchpeer-review

96 Citations (Scopus)

Abstract

Women may expect to spend more than a third of their lives after menopause. Beginning in the sixth decade, many chronic diseases will begin to emerge, which will affect both the quality and quantity of a woman s life. Thus, the onset of menopause heralds an opportunity for prevention strategies to improve the quality of life and enhance longevity. Obesity, metabolic syndrome and diabetes, cardiovascular disease, osteoporosis and osteoarthritis, cognitive decline, dementia and depression, and cancer are the major diseases of concern. Prevention strategies at menopause have to begin with screening and careful assessment for risk factors, which should also include molecular and genetic diagnostics, as these become available. Identification of certain risks will then allow directed therapy. Evidence-based prevention for the diseases noted above include lifestyle management, cessation of smoking, curtailing excessive alcohol consumption, a healthy diet and moderate exercise, as well as mentally stimulating activities. Although the most recent publications from the follow-up studies of the Women s Health Initiative do not recommend menopause hormonal therapy as a prevention strategy, these conclusions may not be fully valid for midlife women, on the basis of the existing data. For healthy women aged 50-59 years, estrogen therapy decreases coronary heart disease and all-cause mortality; this interpretation is entirely consistent with results from other randomized, controlled trials and observational studies. Thus. as part of a comprehensive strategy to prevent chronic disease after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered as part of the armamentarium.
Original languageEnglish
Pages (from-to)540 - 556
Number of pages17
JournalClimacteric
Volume17
Issue number5
DOIs
Publication statusPublished - 2014

Cite this

Lobo, R. A., Davis, S. R., De Villiers, T., Gompel, A., Henderson, V. W., Hodis, H. N., ... Baber, R. (2014). Prevention of diseases after menopause. Climacteric, 17(5), 540 - 556. https://doi.org/10.3109/13697137.2014.933411
Lobo, Rogerio A ; Davis, Susan Ruth ; De Villiers, Tobie ; Gompel, Anne ; Henderson, Victor W ; Hodis, Howard N ; Lumsden, Mary Ann ; Mack, Wendy J ; Shapiro, Samuel ; Baber, Rodney. / Prevention of diseases after menopause. In: Climacteric. 2014 ; Vol. 17, No. 5. pp. 540 - 556.
@article{6f45401cf4484757b7f254de8c0fa3fa,
title = "Prevention of diseases after menopause",
abstract = "Women may expect to spend more than a third of their lives after menopause. Beginning in the sixth decade, many chronic diseases will begin to emerge, which will affect both the quality and quantity of a woman s life. Thus, the onset of menopause heralds an opportunity for prevention strategies to improve the quality of life and enhance longevity. Obesity, metabolic syndrome and diabetes, cardiovascular disease, osteoporosis and osteoarthritis, cognitive decline, dementia and depression, and cancer are the major diseases of concern. Prevention strategies at menopause have to begin with screening and careful assessment for risk factors, which should also include molecular and genetic diagnostics, as these become available. Identification of certain risks will then allow directed therapy. Evidence-based prevention for the diseases noted above include lifestyle management, cessation of smoking, curtailing excessive alcohol consumption, a healthy diet and moderate exercise, as well as mentally stimulating activities. Although the most recent publications from the follow-up studies of the Women s Health Initiative do not recommend menopause hormonal therapy as a prevention strategy, these conclusions may not be fully valid for midlife women, on the basis of the existing data. For healthy women aged 50-59 years, estrogen therapy decreases coronary heart disease and all-cause mortality; this interpretation is entirely consistent with results from other randomized, controlled trials and observational studies. Thus. as part of a comprehensive strategy to prevent chronic disease after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered as part of the armamentarium.",
author = "Lobo, {Rogerio A} and Davis, {Susan Ruth} and {De Villiers}, Tobie and Anne Gompel and Henderson, {Victor W} and Hodis, {Howard N} and Lumsden, {Mary Ann} and Mack, {Wendy J} and Samuel Shapiro and Rodney Baber",
year = "2014",
doi = "10.3109/13697137.2014.933411",
language = "English",
volume = "17",
pages = "540 -- 556",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Taylor & Francis",
number = "5",

}

Lobo, RA, Davis, SR, De Villiers, T, Gompel, A, Henderson, VW, Hodis, HN, Lumsden, MA, Mack, WJ, Shapiro, S & Baber, R 2014, 'Prevention of diseases after menopause', Climacteric, vol. 17, no. 5, pp. 540 - 556. https://doi.org/10.3109/13697137.2014.933411

Prevention of diseases after menopause. / Lobo, Rogerio A; Davis, Susan Ruth; De Villiers, Tobie; Gompel, Anne; Henderson, Victor W; Hodis, Howard N; Lumsden, Mary Ann; Mack, Wendy J; Shapiro, Samuel; Baber, Rodney.

In: Climacteric, Vol. 17, No. 5, 2014, p. 540 - 556.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Prevention of diseases after menopause

AU - Lobo, Rogerio A

AU - Davis, Susan Ruth

AU - De Villiers, Tobie

AU - Gompel, Anne

AU - Henderson, Victor W

AU - Hodis, Howard N

AU - Lumsden, Mary Ann

AU - Mack, Wendy J

AU - Shapiro, Samuel

AU - Baber, Rodney

PY - 2014

Y1 - 2014

N2 - Women may expect to spend more than a third of their lives after menopause. Beginning in the sixth decade, many chronic diseases will begin to emerge, which will affect both the quality and quantity of a woman s life. Thus, the onset of menopause heralds an opportunity for prevention strategies to improve the quality of life and enhance longevity. Obesity, metabolic syndrome and diabetes, cardiovascular disease, osteoporosis and osteoarthritis, cognitive decline, dementia and depression, and cancer are the major diseases of concern. Prevention strategies at menopause have to begin with screening and careful assessment for risk factors, which should also include molecular and genetic diagnostics, as these become available. Identification of certain risks will then allow directed therapy. Evidence-based prevention for the diseases noted above include lifestyle management, cessation of smoking, curtailing excessive alcohol consumption, a healthy diet and moderate exercise, as well as mentally stimulating activities. Although the most recent publications from the follow-up studies of the Women s Health Initiative do not recommend menopause hormonal therapy as a prevention strategy, these conclusions may not be fully valid for midlife women, on the basis of the existing data. For healthy women aged 50-59 years, estrogen therapy decreases coronary heart disease and all-cause mortality; this interpretation is entirely consistent with results from other randomized, controlled trials and observational studies. Thus. as part of a comprehensive strategy to prevent chronic disease after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered as part of the armamentarium.

AB - Women may expect to spend more than a third of their lives after menopause. Beginning in the sixth decade, many chronic diseases will begin to emerge, which will affect both the quality and quantity of a woman s life. Thus, the onset of menopause heralds an opportunity for prevention strategies to improve the quality of life and enhance longevity. Obesity, metabolic syndrome and diabetes, cardiovascular disease, osteoporosis and osteoarthritis, cognitive decline, dementia and depression, and cancer are the major diseases of concern. Prevention strategies at menopause have to begin with screening and careful assessment for risk factors, which should also include molecular and genetic diagnostics, as these become available. Identification of certain risks will then allow directed therapy. Evidence-based prevention for the diseases noted above include lifestyle management, cessation of smoking, curtailing excessive alcohol consumption, a healthy diet and moderate exercise, as well as mentally stimulating activities. Although the most recent publications from the follow-up studies of the Women s Health Initiative do not recommend menopause hormonal therapy as a prevention strategy, these conclusions may not be fully valid for midlife women, on the basis of the existing data. For healthy women aged 50-59 years, estrogen therapy decreases coronary heart disease and all-cause mortality; this interpretation is entirely consistent with results from other randomized, controlled trials and observational studies. Thus. as part of a comprehensive strategy to prevent chronic disease after menopause, menopausal hormone therapy, particularly estrogen therapy may be considered as part of the armamentarium.

UR - http://informahealthcare.com.ezproxy.lib.monash.edu.au/doi/pdf/10.3109/13697137.2014.933411

U2 - 10.3109/13697137.2014.933411

DO - 10.3109/13697137.2014.933411

M3 - Article

VL - 17

SP - 540

EP - 556

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 5

ER -

Lobo RA, Davis SR, De Villiers T, Gompel A, Henderson VW, Hodis HN et al. Prevention of diseases after menopause. Climacteric. 2014;17(5):540 - 556. https://doi.org/10.3109/13697137.2014.933411